Cargando…

Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids

BACKGROUND AND OBJECTIVES: Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids. Elagolix population pharmacokinetics and factors affecting elagolix...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beck, Denise, Winzenborg, Insa, Liu, Mohan, Degner, Jacob, Mostafa, Nael M., Noertersheuser, Peter, Shebley, Mohamad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975762/ https://www.ncbi.nlm.nih.gov/pubmed/34878624 http://dx.doi.org/10.1007/s40262-021-01096-w

Ejemplares similares

Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids
por: Beck, Denise, et al.
Publicado: (2022)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
por: Stodtmann, Sven, et al.
Publicado: (2021)

Correction: Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
por: Abbas Suleiman, Ahmed, et al.
Publicado: (2020)

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model
por: Winzenborg, Insa, et al.
Publicado: (2020)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
por: Nader, Ahmed, et al.
Publicado: (2022)

Integrating real‐world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women
por: Beck, Denise, et al.
Publicado: (2021)

HT update: spotlight on estradiol/norethindrone acetate combination therapy
por: Casey, Colleen L, et al.
Publicado: (2008)

Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women
por: Feldman, Robert A., et al.
Publicado: (2021)

Norethindrone Acetate in the Medical Management of Adenomyosis
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2012)

Unilateral Erythema Nodosum following Norethindrone Acetate, Ethinyl Estradiol, and Ferrous Fumarate Combination Therapy
por: Min, Michelle S., et al.
Publicado: (2016)

Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
por: Chiney, Manoj S., et al.
Publicado: (2019)

Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2021)

A Personalized Medicine Approach Using Clinical Utility Index and Exposure‐Response Modeling Informed by Patient Preferences Data
por: Winzenborg, Insa, et al.
Publicado: (2020)

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist
por: Polepally, Akshanth R., et al.
Publicado: (2020)

Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure
por: Mukherjee, Dwaipayan, et al.
Publicado: (2022)

Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids
por: Al-Hendy, Ayman, et al.
Publicado: (2021)

Medical management of recurrent endometrioma with long-term norethindrone acetate
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2012)

Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data
por: Neri, Manuela, et al.
Publicado: (2019)

Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis
por: Muhammad, Juliawati, et al.
Publicado: (2022)

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids
por: Stewart, Elizabeth A., et al.
Publicado: (2022)

Ultrasound-Guided Diagnosis of Multiple Uterine Fibroids in a Patient With Polycystic Ovaries and Treatment With Relugolix, Estradiol, and Norethisterone Acetate
por: Acchiardo, Joseph, et al.
Publicado: (2023)

Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
por: Snabes, Michael C., et al.
Publicado: (2023)

Ulipristal acetate as a treatment option for uterine fibroids
por: Piecak, Karolina, et al.
Publicado: (2017)

Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
por: Townsend, Robert, et al.
Publicado: (2016)

Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors
por: Arkenau, Hendrik‐Tobias, et al.
Publicado: (2022)

Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids
por: Monleón, Javier, et al.
Publicado: (2014)

Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy
por: Soliman, Ahmed M., et al.
Publicado: (2016)

Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate
por: DiVasta, Amy D., et al.
Publicado: (2021)

Effect of Protease Inhibitors on Steady-State Pharmacokinetics of Oral Norethindrone Contraception in HIV-Infected Women
por: Atrio, Jessica, et al.
Publicado: (2014)

Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids
por: Biglia, Nicoletta, et al.
Publicado: (2014)

Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence
por: Trefoux Bourdet, Alice, et al.
Publicado: (2015)

Safety after extended repeated use of ulipristal acetate for uterine fibroids
por: Fauser, Bart C. J. M., et al.
Publicado: (2017)

Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France
por: Fernandez, Hervé, et al.
Publicado: (2017)

Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids
por: Middelkoop, Mei-An, et al.
Publicado: (2022)

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
por: Simon, James A., et al.
Publicado: (2020)

Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Uterine Fibroids
Publicado: (1903)

Cannot write session to /tmp/vufind_sessions/sess_96ja8hdhtercr9m1b33hmqp5f1